|
MY139563A
(en)
|
2002-09-04 |
2009-10-30 |
Bristol Myers Squibb Co |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
|
US7579360B2
(en)
|
2005-06-09 |
2009-08-25 |
Bristol-Myers Squibb Company |
Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20121506A1
(es)
*
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
AU2007325780B9
(en)
|
2006-11-27 |
2013-09-12 |
H. Lundbeck A/S |
Heteroaryl amide derivatives
|
|
WO2008124153A1
(en)
|
2007-04-10 |
2008-10-16 |
H. Lundbeck A/S |
Heteroaryl amide analogues as p2x7 antagonists
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
WO2009037719A1
(en)
|
2007-09-21 |
2009-03-26 |
Lupin Limited |
Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
|
|
US8324241B2
(en)
|
2008-04-11 |
2012-12-04 |
Bristol-Myers Squibb Company |
Triazolo compounds useful as DGAT1 inhibitors
|
|
US8394823B2
(en)
|
2008-04-11 |
2013-03-12 |
Bristol-Myers Squibb Company |
Triazolopyridine compounds useful as DGAT1 inhibitors
|
|
RU2478636C2
(ru)
|
2008-08-05 |
2013-04-10 |
Дайити Санкио Компани, Лимитед |
ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДИН-2-ОНА, ОБЛАДАЮЩИЕ mTOR ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ
|
|
US8685967B2
(en)
|
2009-04-07 |
2014-04-01 |
Merck Sharp & Dohme Corp. |
Substituted triazolopyridines and analogs thereof
|
|
MY153913A
(en)
*
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
|
US8748457B2
(en)
|
2009-06-18 |
2014-06-10 |
Lupin Limited |
2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors
|
|
CN102725290B
(zh)
*
|
2009-07-27 |
2016-03-09 |
吉利德科学股份有限公司 |
作为离子通道调节剂的稠合杂环化合物
|
|
AU2010328480A1
(en)
*
|
2009-12-08 |
2012-05-17 |
Boehringer Ingelheim International Gmbh |
Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
ES2529119T3
(es)
|
2010-07-02 |
2015-02-17 |
Gilead Sciences, Inc. |
Compuestos heterocíclicos condensados como moduladores de canales iónicos
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
EP2655362A1
(en)
|
2010-12-22 |
2013-10-30 |
Abbvie Inc. |
Hepatitis c inhibitors and uses thereof
|
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2683704B1
(de)
|
2011-03-08 |
2014-12-17 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120054A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120056A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
JP2014509616A
(ja)
*
|
2011-03-31 |
2014-04-21 |
エーエムベーエルエーエム テクノロジー トランスファー ゲーエムベーハー |
治療用イミダゾ［１，２−ａ］ピリジン化合物
|
|
TWI510480B
(zh)
|
2011-05-10 |
2015-12-01 |
Gilead Sciences Inc |
充當離子通道調節劑之稠合雜環化合物
|
|
TWI549944B
(zh)
|
2011-07-01 |
2016-09-21 |
吉李德科學股份有限公司 |
作為離子通道調節劑之稠合雜環化合物
|
|
NO3175985T3
(enExample)
|
2011-07-01 |
2018-04-28 |
|
|
|
UY34305A
(es)
|
2011-09-01 |
2013-04-30 |
Novartis Ag |
Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
ES2689429T3
(es)
*
|
2012-07-13 |
2018-11-14 |
Ucb Biopharma Sprl |
Derivados de imidazopiridina como moduladores de actividad de TNF
|
|
IN2015DN03795A
(enExample)
|
2012-10-24 |
2015-10-02 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
RU2632884C2
(ru)
*
|
2013-03-29 |
2017-10-11 |
Тейдзин Фарма Лимитед |
Производное пиразола
|
|
SG11201601044XA
(en)
|
2013-08-12 |
2016-03-30 |
Genentech Inc |
Compositions and method for treating complement-associated conditions
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
TWI664164B
(zh)
|
2014-02-13 |
2019-07-01 |
美商英塞特控股公司 |
作為ｌｓｄ１抑制劑之環丙胺
|
|
WO2015123408A1
(en)
|
2014-02-13 |
2015-08-20 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
WO2015123437A1
(en)
|
2014-02-13 |
2015-08-20 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
PE20161573A1
(es)
|
2014-02-13 |
2017-01-19 |
Incyte Corp |
Ciclopropilamina como inhibidor de la lsd1
|
|
CN106536561A
(zh)
|
2014-05-01 |
2017-03-22 |
豪夫迈·罗氏有限公司 |
抗‑因子d抗体变体及其用途
|
|
WO2016007722A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
US9695180B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
|
|
US9758523B2
(en)
|
2014-07-10 |
2017-09-12 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as LSD1 inhibitors
|
|
US9695168B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
CN105503877A
(zh)
|
2014-09-24 |
2016-04-20 |
和记黄埔医药（上海）有限公司 |
咪唑并哒嗪类化合物及其用途
|
|
EP3197870B1
(en)
|
2014-09-25 |
2020-08-19 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10426818B2
(en)
|
2015-03-24 |
2019-10-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method and pharmaceutical composition for use in the treatment of diabetes
|
|
MY191796A
(en)
|
2015-04-03 |
2022-07-15 |
Incyte Corp |
Heterocyclic compounds as lsd1 inhibitors
|
|
EP3280708B1
(en)
|
2015-04-10 |
2021-09-01 |
Araxes Pharma LLC |
Substituted quinazoline compounds and methods of use thereof
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
KR102710120B1
(ko)
|
2015-08-12 |
2024-09-27 |
인사이트 홀딩스 코포레이션 |
Lsd1 저해제의 염
|
|
WO2017058915A1
(en)
*
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
MA52119A
(fr)
|
2015-10-19 |
2018-08-29 |
Ncyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
|
HK1257422A1
(zh)
|
2015-10-30 |
2019-10-18 |
豪夫迈‧罗氏有限公司 |
抗-因子d抗体变体缀合物及其用途
|
|
EA038635B9
(ru)
|
2015-11-16 |
2021-10-26 |
Араксис Фарма Ллк |
2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
|
|
PT3377488T
(pt)
|
2015-11-19 |
2022-11-21 |
Incyte Corp |
Compostos heterocíclicos como imunomoduladores
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
SI3394033T1
(sl)
|
2015-12-22 |
2021-03-31 |
Incyte Corporation |
Heterociklične spojine kot imunomodulatorji
|
|
PE20190377A1
(es)
|
2016-04-22 |
2019-03-08 |
Incyte Corp |
Formulaciones de un inhibidor de lsd 1
|
|
WO2017192961A1
(en)
|
2016-05-06 |
2017-11-09 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
EP3464279B1
(en)
|
2016-05-26 |
2021-11-24 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
PL3472167T3
(pl)
|
2016-06-20 |
2022-12-19 |
Incyte Corporation |
Związki heterocykliczne jako immunomodulatory
|
|
US11352328B2
(en)
|
2016-07-12 |
2022-06-07 |
Arisan Therapeutics Inc. |
Heterocyclic compounds for the treatment of arenavirus
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
EP3484866B1
(en)
|
2016-07-14 |
2022-09-07 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
ES2941716T3
(es)
|
2016-08-29 |
2023-05-25 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
EP3519402A1
(en)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
WO2018119286A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
|
KR102696516B1
(ko)
|
2016-12-22 |
2024-08-22 |
인사이트 코포레이션 |
면역조절제로서의 벤조옥사졸 유도체
|
|
MY197501A
(en)
|
2016-12-22 |
2023-06-19 |
Incyte Corp |
Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
|
|
US20180179201A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
EP3558973B1
(en)
|
2016-12-22 |
2021-09-15 |
Incyte Corporation |
Pyridine derivatives as immunomodulators
|
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
EP3573967A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
CA3063440A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Covalent inhibitors of kras
|
|
CN110831933A
(zh)
|
2017-05-25 |
2020-02-21 |
亚瑞克西斯制药公司 |
喹唑啉衍生物作为突变kras、hras或nras的调节剂
|
|
EP4212529B1
(en)
|
2018-03-30 |
2025-01-29 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
FI4219492T3
(fi)
|
2018-05-11 |
2025-02-17 |
Incyte Corp |
Heterosyklisiä yhdisteitä immunomodulaattoreina
|
|
EP3829580A1
(en)
|
2018-08-01 |
2021-06-09 |
Araxes Pharma LLC |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|
|
US12419865B2
(en)
|
2018-12-06 |
2025-09-23 |
Arisan Therapeutics Inc. |
Compounds for the treatment of arenavirus infection
|
|
CA3150434A1
(en)
|
2019-08-09 |
2021-02-18 |
Incyte Corporation |
Salts of a pd-1/pd-l1 inhibitor
|
|
AR120109A1
(es)
|
2019-09-30 |
2022-02-02 |
Incyte Corp |
Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
|
|
EP4038070B1
(en)
|
2019-09-30 |
2025-07-09 |
Janssen Pharmaceutica NV |
Radiolabelled mgl pet ligands
|
|
IL292524A
(en)
|
2019-11-11 |
2022-06-01 |
Incyte Corp |
Salts and crystalline forms of a pd-1/pd-l1 inhibitor
|
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
|
PE20231438A1
(es)
|
2020-11-06 |
2023-09-14 |
Incyte Corp |
Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo
|
|
WO2022099075A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Crystalline form of a pd-1/pd-l1 inhibitor
|